E-ISSN: 2147-1959
Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
PDF
Cite
Share
Request
Interesting Image
VOLUME: 30 ISSUE: 2
P: 107-109
June 2021

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action

Mol Imaging Radionucl Ther 2021;30(2):107-109
DOI: 10.4274/mirt.galenos.2020.69783
Majid Assadi 1
Seyed Javad Rekabpour 2
Abdullatif Amini 3
Habibollah Dadgar 4
Reza Nemati 5
Ali Gholamrezanezhad 6
Iraj Nabipour 7
Esmail Jafari 1
Hojjat Ahmadzadehfar 8
1. Bushehr University of Medical Sciences, Bushehr Medical University Hospital, The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy, Bushehr, Iran
2. Bushehr University of Medical Sciences, Bushehr Medical University Hospital, Department of Oncology, Bushehr, Iran
3. Bushehr University of Medical Sciences, Bushehr Medical Heart Center, Department of Cardiology, Bushehr, Iran
4. Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran
5. Bushehr University of Medical Sciences, Bushehr Medical University Hospital, Department of Neurology, Bushehr, Iran
6. University of Southern California, Keck School of Medicine, Department of Radiology, Los Angeles, USA
7. Bushehr University of Medical Sciences, Bushehr Medical University Hospital, Department of Internal Medicine, Division of Endocrinology, Bushehr, Iran
8. Klinikum Westfalen, Department of Nuclear Medicine, Dortmund, Germany
No information available.
No information available
Received Date: 10.08.2019
Accepted Date: 14.04.2020
Publish Date: 03.06.2021
PDF
Cite
Share
Request

ABSTRACT

We present a partial response of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In addition to the valuable role of PRRT in inoperable NETs, it has been demonstrated that this treatment can be a promising therapy for progressive meningioma, especially in patients with low grade and refractory to standard regime.

References

1
Makis W, McCann K, McEwan AJ. Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT. Clin Nucl Med 2015;40:237-240.
2
Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Aricò D, Sansovini M, Paganelli G. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 2009;36:1407-1416.
3
Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer 2019;26:227-239.
4
Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, Weller M, Schaefer N, Kuhn FP. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? Neuro Oncol 2016;18:1021-1027.
5
Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, Ilhan H, Pangalu A, Weller M, Tonn JC, Sommerauer M, Albert NL. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol 2016;18:1538-1547.